January 31, 2018 / 11:12 AM / 3 months ago

BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study

Jan 31 (Reuters) - Sage Therapeutics Inc:

* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS

* SAGE THERAPEUTICS - SAGE-217 MET PRIMARY ENDPOINT OF IMPROVED SLEEP EFFICIENCY AND DEMONSTRATED IMPROVEMENTS IN MAINTAINING SLEEP COMPARED TO PLACEBO

* SAGE THERAPEUTICS INC - SAGE-217 WAS GENERALLY WELL TOLERATED AND ALL ADVERSE EVENTS WERE MILD

* SAGE THERAPEUTICS INC - BASED ON THE POSITIVE RESULTS, SAGE EXPECTS TO INITIATE CLINICAL DEVELOPMENT OF SAGE-217 IN DISORDERS OF SLEEP IN 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below